Sort by
Refine Your Search
-
) Positions PhD Positions Country Israel Application Deadline 20 Jun 2025 - 10:34 (Asia/Jerusalem) Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme
-
) Positions PhD Positions Country Israel Application Deadline 3 Jul 2025 - 10:46 (Asia/Jerusalem) Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme
-
) Positions PhD Positions Country Israel Application Deadline 10 Jan 2026 - 14:20 (Asia/Jerusalem) Type of Contract Temporary Job Status Full-time Offer Starting Date 10 Feb 2025 Is the job funded through
-
Letters, he is now continuing his work at the Hebrew University of Jerusalem. Funding: A monthly scholarship, ranging from 6,500 to 8,000 NIS, which increases annually. Typically, PhD students are also
-
) Positions PhD Positions Country Israel Application Deadline 21 Jun 2025 - 15:14 (Asia/Jerusalem) Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme
-
(R3) Positions PhD Positions Country Israel Application Deadline 31 May 2025 - 14:45 (Asia/Jerusalem) Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework
-
We are seeking a highly motivated and creative PhD student to investigate how the nervous system regulates iron availability and mitochondrial function in intestinal and muscle cells. This project will
-
transportation. About our School: The position falls under The Koret School of Veterinary Medicine, but it's open to postdocs and PhD students from other fields. The nature of the research is basic science, not
-
Profile Established Researcher (R3) Positions PhD Positions Country Israel Application Deadline 1 Aug 2025 - 10:29 (Asia/Jerusalem) Type of Contract Temporary Job Status Full-time Is the job funded through
-
🔬 Exciting Research Opportunity: PhD/MSc Position in Cancer Therapeutics🏢 Eastern R&D Center, Israel, Ariel University, Israel.Our lab is pioneering peptide-based theranostic agents